OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 04, 2022
EMA’s PRIME scheme has enabled life-changing medicines to become available to patients at a faster rate.
Evonik has increased its global supply of plant-derived cholesterol used for mRNA vaccines and gene therapies.
March 03, 2022
TFF Pharmaceuticals and Catalent will collaborate to develop TFF's platform for manufacturing dry powder particles.
Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.
Technological advances are helping shape the dosage forms of the future.
Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.
Bacteriophages could be crucial weapons in the fight against antibiotic-resistant bacteria.
March 02, 2022
Adagene has announced SAFEbody multi-target collaboration with Sanofi for novel masked immuno-oncology antibody candidates.
AbbVie has acquired Syndesi Therapeutics, expanding AbbVie’s neuroscience portfolio.
Borrowing is good, but invention is best.